Lakefront Biotherapeutics (GLPGF) EBIT Growth (3y) (2017 - 2026)
Powered by 
Analysis
Lakefront Biotherapeutics (GLPGF) EBIT Growth (3y) (2017 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.13 Bn | 197.14 Bn | 7.24 Bn | 9.40% |
| 2 | Gilead Sciences | 181.20 Bn | 178.03 Bn | 6.22 Bn | -102.00% |
| 3 | Vertex Pharmaceuticals | 132.23 Bn | 124.38 Bn | 2.84 Bn | 6.70% |
| 4 | Regeneron Pharmaceuticals | 82.91 Bn | 74.92 Bn | 3.93 Bn | 8.36% |
| 5 | Argenx Se | 61.59 Bn | 56.41 Bn | 1.37 Bn | 89.72% |
| 6 | Moderna | 55.02 Bn | 49.89 Bn | 52.00 Mn | 24.14% |
| 7 | Alnylam Pharmaceuticals | 34.05 Bn | 30.74 Bn | 992.69 Mn | 44.34% |
| 8 | Biogen | 31.30 Bn | 30.01 Bn | 1.96 Bn | -96.48% |
| 9 | Roivant Sciences | 30.18 Bn | 30.18 Bn | 1.16 Mn | - |
| 10 | Lakefront Biotherapeutics | 1.73 Bn | 1.73 Bn | 3.51 Mn | -50.94% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -50.94% |
| Mar 31, 2026 | -69.78% |
| Dec 31, 2025 | 499.98% |
| Sep 30, 2025 | -96.69% |
| Jun 30, 2025 | 7.49% |
| Mar 31, 2025 | -91.60% |
| Dec 31, 2024 | 152.61% |
| Sep 30, 2024 | -0.92% |
| Jun 30, 2024 | 57.94% |
| Mar 31, 2024 | 16.25% |
| Dec 31, 2023 | 45.78% |
| Sep 30, 2023 | 57.09% |
| Jun 30, 2023 | 46.70% |
| Mar 31, 2023 | 33.15% |
| Dec 31, 2022 | 29.10% |
| Sep 30, 2022 | -27.78% |
| Jun 30, 2022 | -17.79% |
| Mar 31, 2022 | 26.80% |
| Dec 31, 2021 | -13.66% |
| Sep 30, 2021 | -154.67% |